OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
CTOR$0.9859

Citius Oncology Inc

Biotechnology & Medical ResearchVerified

Citius Oncology Inc has a market capitalization of $86.89 million and a price-to-book ratio of 1.94, indicating that the market values the company at a premium to its book value. The company's liquidity position is weak, with a current ratio of 0.56, suggesting that it may struggle to meet short-term obligations with its current assets. The company's cash and equivalents amount to $3.92 million, which is significantly lower than its total liabilities of $56.08 million, further highlighting its liquidity constraints. The company's profitability is negative, with a return on equity of -55.19% and a return on assets of -24.53%, indicating that it is not generating returns for its shareholders or effectively utilizing its assets. The operating income for the period is -$23.52 million, and the net income is -$24.76 million, reflecting a significant loss. The company's debt-to-equity ratio is 0.08, suggesting that it is not heavily leveraged, but the negative returns indicate poor operational performance. Citius Oncology Inc does not report segment or geographic revenue data in the provided financial snapshot, making it difficult to assess the company's exposure to different markets or product lines. The lack of detailed segment information limits the ability to evaluate the company's diversification and potential growth drivers. The company's growth trajectory is uncertain, as there is no revenue history provided to assess past performance. The absence of historical data makes it challenging to project future growth or evaluate the effectiveness of the company's strategies. The company's current financial position, characterized by significant losses and weak liquidity, suggests that it may face challenges in sustaining operations without additional financing. The risk assessment indicates that the company has low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative operating and net income, combined with its weak liquidity position, suggests that it may need to raise additional capital in the near term, which could lead to dilution for existing shareholders. The company's reliance on external financing to fund operations increases the risk of dilution and potential loss of control for current investors. Recent events and filings do not provide specific details on the company's operations or strategic initiatives. The lack of recent events or transcripts limits the ability to assess the company's current direction and management's response to market conditions. The company's financial performance and strategic decisions will be critical in determining its future prospects.

30-day price · CTOR+0.40 (+77.2%)
Low$0.49High$1.00Close$0.91As of10 May, 00:00 UTC
Profile
CompanyCitius Oncology Inc
TickerCTOR.O
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. Citius Oncology Inc is a biotechnology company focused on the development and commercialization of novel therapies for the treatment of cancer, primarily through its proprietary drug delivery platform.

Classification. Citius Oncology Inc is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Biotechnology & Medical Research industry, with a classification confidence of 0.92.

Citius Oncology Inc has a market capitalization of $86.89 million and a price-to-book ratio of 1.94, indicating that the market values the company at a premium to its book value. The company's liquidity position is weak, with a current ratio of 0.56, suggesting that it may struggle to meet short-term obligations with its current assets. The company's cash and equivalents amount to $3.92 million, which is significantly lower than its total liabilities of $56.08 million, further highlighting its liquidity constraints. The company's profitability is negative, with a return on equity of -55.19% and a return on assets of -24.53%, indicating that it is not generating returns for its shareholders or effectively utilizing its assets. The operating income for the period is -$23.52 million, and the net income is -$24.76 million, reflecting a significant loss. The company's debt-to-equity ratio is 0.08, suggesting that it is not heavily leveraged, but the negative returns indicate poor operational performance. Citius Oncology Inc does not report segment or geographic revenue data in the provided financial snapshot, making it difficult to assess the company's exposure to different markets or product lines. The lack of detailed segment information limits the ability to evaluate the company's diversification and potential growth drivers. The company's growth trajectory is uncertain, as there is no revenue history provided to assess past performance. The absence of historical data makes it challenging to project future growth or evaluate the effectiveness of the company's strategies. The company's current financial position, characterized by significant losses and weak liquidity, suggests that it may face challenges in sustaining operations without additional financing. The risk assessment indicates that the company has low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative operating and net income, combined with its weak liquidity position, suggests that it may need to raise additional capital in the near term, which could lead to dilution for existing shareholders. The company's reliance on external financing to fund operations increases the risk of dilution and potential loss of control for current investors. Recent events and filings do not provide specific details on the company's operations or strategic initiatives. The lack of recent events or transcripts limits the ability to assess the company's current direction and management's response to market conditions. The company's financial performance and strategic decisions will be critical in determining its future prospects.
Key takeaways
  • Citius Oncology Inc is a biotechnology company with a focus on cancer treatments, but it is currently experiencing significant financial losses.
  • The company's liquidity position is weak, with a current ratio of 0.56 and a cash balance of $3.92 million.
  • The company's profitability is negative, with a return on equity of -55.19% and a return on assets of -24.53%.
  • The company does not provide segment or geographic revenue data, making it difficult to assess diversification and growth drivers.
  • The company's growth trajectory is uncertain due to the lack of historical revenue data and its current financial position.
  • The company has low liquidity and dilution risk, but its financial performance suggests a need for additional financing, which could lead to dilution for existing shareholders.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$0.00
Gross profit
Operating income-$23.5M
Net income-$24.8M
R&D
SG&A
D&A
SBC
Operating cash flow-$5.5M
CapEx
Free cash flow-$24.8M
Total assets$100.9M
Total liabilities$56.1M
Total equity$44.9M
Cash & equivalents$3.9M
Long-term debt$3.8M
Valuation
Market price$0.98
Market cap$86.9M
Enterprise value$86.8M
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B1.9
P/Tangible book1.9
Tangible book$44.9M
Net cash$124.8k
Current ratio0.6
Debt/Equity0.1
ROA-24.5%
ROE-55.2%
Cash conversion22.0%
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 693 companies
MetricCTORActivity
Op margin2.4% medp25 -91.8% · p75 12.5%
Net margin1.2% medp25 -98.4% · p75 10.4%
Gross margin45.6% medp25 29.8% · p75 66.7%
CapEx / revenue-5.2% medp25 -15.8% · p75 -1.7%
Debt / equity8.0%9.3% medp25 0.1% · p75 43.8%below median
Observations
IR observations
Mean price target6.00 USD
Median price target6.00 USD
High price target6.00 USD
Low price target6.00 USD
Mean recommendation3.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count0.00
Hold count1.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate-0.19 USD
Last actual EPS-0.34 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-16 15:16 UTC#b7b138e7
Market quoteclose USD 0.90 · shares 0.09B diluted
no public URL
2026-05-16 15:18 UTC#f71bed16
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 17:26 UTCJob: 141d8545